Global Urine Exosome Isolation Kit Market Strategic Research Report
By Type: Precipitation-based Kits, Ultrafiltration-based Kits, Size Exclusion Chromatography Kits, Immunoaffinity Capture Kits, Ultracentrifugation-assisted Kits
By Application: Research, Clinical, Others
Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America
Key Players: Thermo Fisher Scientific, Qiagen, Bio-Techne Corporation, System Biosciences, Miltenyi Biotec, Norgen Biotek, Lonza Group, Takara Bio, Abcam, Izon Science, Tiangen Biotech, Transgen Biotech, BGI Genomics, Mgi Tech, Shanghai Genmed Biotechnology, Beyotime Biotechnology, Servicebio Technology
개요
Scope of the Report
The global Urine Exosome Isolation Kit market size is predicted to grow from US$ 304 million in 2025 to US$ 786 million in 2032; it is expected to grow at a CAGR of 14.6% from 2026 to 2032.
A Urine Exosome Isolation Kit is a laboratory reagent kit designed to extract and purify exosomes from urine samples. It typically uses methods such as precipitation, membrane filtration, ultracentrifugation assistance, or affinity-based capture to isolate nanosized extracellular vesicles (exosomes) from urine for downstream applications like biomarker research, disease diagnosis, and molecular analysis.In 2025, global Urine Exosome Isolation Kit production reached approximately 0.817 M units, with an average global market price of around US$ 380 per unit. Annual production capacity is 1.12 M units. Gross Profit Margin: 68%.The industry chain of urine exosome isolation kits consists of three main layers: upstream raw material suppliers, midstream kit manufacturers, and downstream end users. Upstream includes reagents, antibodies, membranes, and chromatography materials that determine extraction efficiency and purity. Midstream manufacturers such as life science tool companies integrate these components into standardized kits using technologies like precipitation, ultrafiltration, SEC, and immunoaffinity capture. Downstream demand mainly comes from academic research institutions, biotechnology companies, and clinical laboratories focused on kidney disease, bladder cancer, and non-invasive liquid biopsy applications. Urine exosome isolation kits sit at an early but structurally important stage of precision diagnostics. The most critical value driver is not volume but data quality, meaning purity and reproducibility dominate purchasing decisions. Although the market is still largely research-use-only, the transition toward clinical validation in urology and nephrology is accelerating. In my view, the long-term growth potential depends on whether standardized urine EV isolation workflows can be established and integrated into routine diagnostic pipelines.
Global key Urine Exosome Isolation Kit players cover Thermo Fisher Scientific, Qiagen, Bio-Techne Corporation, System Biosciences, Miltenyi Biotec, etc.
Key Questions Addressed in this Report
What is the 10-year outlook for the global Urine Exosome Isolation Kit market?
What factors are driving Urine Exosome Isolation Kit market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Urine Exosome Isolation Kit market opportunities vary by end market size?
How does Urine Exosome Isolation Kit break out by Isolation Technology, by Application?
This report presents a comprehensive overview of the global Urine Exosome Isolation Kit market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.
Segment by Isolation Technology
- Precipitation-based Kits
- Ultrafiltration-based Kits
- Size Exclusion Chromatography Kits
- Immunoaffinity Capture Kits
- Ultracentrifugation-assisted Kits
Segment by Automation Level
- Manual Kits
- Semi-automated Kits
- Fully Automated Systems Kits
Segment by Purity Performance
- High-purity: ≥10⁹–10¹¹
- Medium-purity: 10⁸–10⁹
- Low-purity: 10⁷–10⁸
Segment by Application
- Research
- Clinical
- Others
Who Can Use This Report?
This report is written for decision-makers who need a clear, data-backed view of the global Urine Exosome Isolation Kit market:
- Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
- Distributors, channel partners and end users in Research, Clinical, Others evaluating demand and sourcing options
- Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
- Government agencies, industry associations and research institutions tracking industry developments and policy impact
Market snapshot
Global Urine Exosome Isolation Kit Market Strategic Research Report snapshot, 2025–2032
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.Segments covered in this report
Table of contents
01Executive Summary
02Industry Overview & Forecast
- 2.1.1 Market Definition and Scope
- 2.1.2 Market Size and Growth Forecast
- 2.1.3 Volume Analysis
- 2.1.4 Segment Outlook by Type
- 2.1.5 Segment Outlook by Application
- 2.1.6 Regional Outlook
- 2.1.7 Structural Developments Shaping the Forecast
- 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
- 3.1 Market Segmentation by Type
- 3.1.1 Market by Type Overview
- 3.1.2 Precipitation-based Kits
- 3.1.3 Ultrafiltration-based Kits
- 3.1.4 Size Exclusion Chromatography Kits
- 3.1.5 Immunoaffinity Capture Kits
- 3.1.6 Ultracentrifugation-assisted Kits
- 3.1.7 Volume Analysis
04Market Segmentation by Application
- 4.1 Market Segmentation by Application
- 4.1.1 Market by Application Overview
- 4.1.2 Research
- 4.1.3 Clinical
- 4.1.4 Others
- 4.1.5 Volume Analysis
05Regional Market Forecast
- Asia Pacific
- North America
- Europe
- Middle East & Africa
- Latin America
06Country-Level Market Forecast
- 6.1 Asia Pacific
- 6.1.1 China
- 6.1.2 Japan
- 6.1.3 Korea
- 6.1.4 Southeast Asia
- 6.1.5 India
- 6.1.6 Australia
- 6.1.7 Rest of Asia Pacific
- 6.2 North America
- 6.2.1 United States
- 6.2.2 Canada
- 6.2.3 Mexico
- 6.2.4 Rest of North America
- 6.3 Europe
- 6.3.1 Germany
- 6.3.2 France
- 6.3.3 UK
- 6.3.4 Italy
- 6.3.5 Russia
- 6.3.6 Rest of Europe
- 6.4 Middle East & Africa
- 6.4.1 Egypt
- 6.4.2 South Africa
- 6.4.3 Israel
- 6.4.4 Turkey
- 6.4.5 GCC Countries
- 6.4.6 Rest of Middle East & Africa
- 6.5 Latin America
- 6.5.1 Brazil
- 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
- 7.1 Growth Drivers & Inhibitors
- 7.1.1 Section Overview
- 7.1.2 Growth Drivers
- 7.1.3 Growth Inhibitors
- 7.1.4 Driver and Inhibitor Impact Assessment
- 7.1.5 Analyst Perspective
08Key Company Profiles
- 8.1 Thermo Fisher Scientific
- 8.1.1 Company Overview
- 8.1.2 Key Products & Segments
- 8.1.3 Financial Performance (2023–2025)
- 8.1.4 Business Strategy
- 8.1.5 SWOT Analysis
- 8.1.6 Strategic Implications (2026–2032)
- 8.2 Qiagen
- 8.2.1 Company Overview
- 8.2.2 Key Products & Segments
- 8.2.3 Financial Performance (2023–2025)
- 8.2.4 Business Strategy
- 8.2.5 SWOT Analysis
- 8.2.6 Strategic Implications (2026–2032)
- 8.3 Bio-Techne Corporation
- 8.3.1 Company Overview
- 8.3.2 Key Products & Segments
- 8.3.3 Financial Performance (2023–2025)
- 8.3.4 Business Strategy
- 8.3.5 SWOT Analysis
- 8.3.6 Strategic Implications (2026–2032)
- 8.4 System Biosciences
- 8.4.1 Company Overview
- 8.4.2 Key Products & Segments
- 8.4.3 Financial Performance (2023–2025)
- 8.4.4 Business Strategy
- 8.4.5 SWOT Analysis
- 8.4.6 Strategic Implications (2026–2032)
- 8.5 Miltenyi Biotec
- 8.5.1 Company Overview
- 8.5.2 Key Products & Segments
- 8.5.3 Financial Performance (2023–2025)
- 8.5.4 Business Strategy
- 8.5.5 SWOT Analysis
- 8.5.6 Strategic Implications (2026–2032)
- 8.6 Norgen Biotek
- 8.6.1 Company Overview
- 8.6.2 Key Products & Segments
- 8.6.3 Financial Performance (2023–2025)
- 8.6.4 Business Strategy
- 8.6.5 SWOT Analysis
- 8.6.6 Strategic Implications (2026–2032)
- 8.7 Lonza Group
- 8.7.1 Company Overview
- 8.7.2 Key Products & Segments
- 8.7.3 Financial Performance (2023–2025)
- 8.7.4 Business Strategy
- 8.7.5 SWOT Analysis
- 8.7.6 Strategic Implications (2026–2032)
- 8.8 Takara Bio
- 8.8.1 Company Overview
- 8.8.2 Key Products & Segments
- 8.8.3 Financial Performance (2023–2025)
- 8.8.4 Business Strategy
- 8.8.5 SWOT Analysis
- 8.8.6 Strategic Implications (2026–2032)
- 8.9 Abcam
- 8.9.1 Company Overview
- 8.9.2 Key Products & Segments
- 8.9.3 Financial Performance (2023–2025)
- 8.9.4 Business Strategy
- 8.9.5 SWOT Analysis
- 8.9.6 Strategic Implications (2026–2032)
- 8.10 Izon Science
- 8.10.1 Company Overview
- 8.10.2 Key Products & Segments
- 8.10.3 Financial Performance (2023–2025)
- 8.10.4 Business Strategy
- 8.10.5 SWOT Analysis
- 8.10.6 Strategic Implications (2026–2032)
- 8.11 Tiangen Biotech
- 8.11.1 Company Overview
- 8.11.2 Key Products & Segments
- 8.11.3 Financial Performance (2023–2025)
- 8.11.4 Business Strategy
- 8.11.5 SWOT Analysis
- 8.11.6 Strategic Implications (2026–2032)
- 8.12 Transgen Biotech
- 8.12.1 Company Overview
- 8.12.2 Key Products & Segments
- 8.12.3 Financial Performance (2023–2025)
- 8.12.4 Business Strategy
- 8.12.5 SWOT Analysis
- 8.12.6 Strategic Implications (2026–2032)
- 8.13 BGI Genomics
- 8.13.1 Company Overview
- 8.13.2 Key Products & Segments
- 8.13.3 Financial Performance (2023–2025)
- 8.13.4 Business Strategy
- 8.13.5 SWOT Analysis
- 8.13.6 Strategic Implications (2026–2032)
- 8.14 Mgi Tech
- 8.14.1 Company Overview
- 8.14.2 Key Products & Segments
- 8.14.3 Financial Performance (2023–2025)
- 8.14.4 Business Strategy
- 8.14.5 SWOT Analysis
- 8.14.6 Strategic Implications (2026–2032)
- 8.15 Shanghai Genmed Biotechnology
- 8.15.1 Company Overview
- 8.15.2 Key Products & Segments
- 8.15.3 Financial Performance (2023–2025)
- 8.15.4 Business Strategy
- 8.15.5 SWOT Analysis
- 8.15.6 Strategic Implications (2026–2032)
- 8.16 Beyotime Biotechnology
- 8.16.1 Company Overview
- 8.16.2 Key Products & Segments
- 8.16.3 Financial Performance (2023–2025)
- 8.16.4 Business Strategy
- 8.16.5 SWOT Analysis
- 8.16.6 Strategic Implications (2026–2032)
- 8.17 Servicebio Technology
- 8.17.1 Company Overview
- 8.17.2 Key Products & Segments
- 8.17.3 Financial Performance (2023–2025)
- 8.17.4 Business Strategy
- 8.17.5 SWOT Analysis
- 8.17.6 Strategic Implications (2026–2032)
09Competitive Landscape
- 9.1 Competitive Landscape Overview
- 9.2 Competitive Intensity Assessment
- 9.3 Key Player Strategies & Positioning
- 9.4 Competitive Dynamics & Strategic Outlook
- 9.4.1 Emerging Competitive Threats
- 9.4.2 Consolidation vs. Fragmentation Outlook
- 9.4.3 Competitive Response Matrix
- 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
- 10.1 Threat of New Entrants
- 10.2 Bargaining Power of Buyers
- 10.3 Bargaining Power of Suppliers
- 10.4 Threat of Substitutes
- 10.5 Competitive Rivalry
11PESTLE Analysis
- 11.1 Political
- 11.2 Economic
- 11.3 Social and Demographic
- 11.4 Technological
- 11.5 Legal and Regulatory
- 11.6 Environmental
- 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
- 13.1 Future Trends & Outlook
- 13.1.1 Trend Summary and Commercial Maturity Assessment
- 13.1.2 Technology and Innovation Trends
- 13.1.3 Long-Term Market Outlook
- 13.1.4 Investment & M&A Activity Outlook
- 13.1.5 Overall Outlook Assessment
Frequently asked questions
What is the size of the global Urine Exosome Isolation Kit market?
What is the forecast CAGR for the Urine Exosome Isolation Kit market?
What is Urine Exosome Isolation Kit?
What are the main segments of the Urine Exosome Isolation Kit market by isolation technology?
Which applications drive demand in the Urine Exosome Isolation Kit market?
Who are the key players in the Urine Exosome Isolation Kit market?
Which regions and countries are covered for Urine Exosome Isolation Kit?
What is driving growth in the Urine Exosome Isolation Kit market?
Who should buy the Urine Exosome Isolation Kit market report?
What license options are available for this report?
Research Methodology
All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.
Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.
Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.
Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.
CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.
All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.
On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.
Need a customized version?
Get country-, segment- or company-specific intelligence tailored to your exact requirements.
Request custom research →Request a free sample
Receive a sample of Global Urine Exosome Isolation Kit Market Strategic Research Report before you buy.
Customize This Report
Describe your specific requirements and our analysts will scope and deliver a tailored version.
Request Invoice
We will email a proforma invoice within 24 hours. Report access is granted upon payment confirmation.
Navadhi Market Research · Healthcare & Medical Devices